This dataset contains complete product information for all approved, marketed, canceled and dormant products for human, veterinary, disinfectant and radiopharmaceutical use in the Canadian Drug Product Database (DPD) as of September 1, 2017. Before drug products are authorized for sale in Canada, Health Canada reviews them to assess the safety, efficacy, and quality. Drug products include prescription and non-prescription pharmaceuticals, disinfectants and sanitizers with disinfectant claims.

This data package contains complete information on all approved, marketed, canceled and dormant products for human, veterinary, disinfectant and radiopharmaceutical use in New Zealand, Germany, United Kingdom (UK) and Canada.

This dataset contains complete active ingredient information for all approved, marketed, canceled and dormant products for human, veterinary, disinfectant and radiopharmaceutical use in the Canadian Drug Product Database (DPD) as of September 1, 2017. Before drug products are authorized for sale, Health Canada reviews them to assess their safety, efficacy, and quality. Drug products include prescription and non-prescription pharmaceuticals, disinfectants and sanitizers with disinfectant claims.

The Canadian Drug Product Database (DPD) contains product specific information on drugs approved for use in Canada, and includes human pharmaceutical and biological drugs, veterinary drugs and disinfectant products. This information includes 'brand name', 'route of administration' and a Canadian 'Drug Identification Number' (DIN).

The Drug Product Database (DPD) system captures information on Canadian human, veterinary and disinfectant products approved for use by Health Canada. To facilitate the use of the drug product data, multiple Drug Product files are available. Users can access the complete data set through the “Drug Product” file. Subsets of the data can be accessed in the “Drug Product By …” files. The data in these files are filtered based on the current drug product status. For example, only drug product data for Approved products will be found in the “Drug Product By Approved Status” file.

The dataset New Zealand Drug Product Database lists all drug products that have been given consent to market in New Zealand by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE).

Public Health Canada

Drug Products Database Dump

This is publicly accessible open data uploaded here for easy of use. Files can also directly be downloaded from here: https://health-products.canada.ca/api/drug/ Updated as of January 5 2025

The Drug Product Database (DPD) system captures information on Canadian human, veterinary and disinfectant products approved for use by Health Canada. To facilitate the use of the drug product data, multiple Drug Product files are available. Users can access the complete data set through the “Drug Product” file. Subsets of the data can be accessed in the “Drug Product By …” files. The data in these files are filtered based on the current drug product status. For example, only drug product data for Approved products will be found in the “Drug Product By Approved Status” file.

This dataset contains the Product part to build the Drugs@FDA database. Drugs at FDA is a database of FDA Approved Drug Products available on the FDA official website. It provides information of drug (generic) name, active ingredient, form and strength available, FDA application number, label info, dosage form or route, marketing status and pharmaceutical company as well as patient information, approval letters, review and other facts for drugs approved after 1997.

List showing the name of product, name of registration certificate holder, Hong Kong registration number (Permit No) and active ingredient(s) of each registered pharmaceutical product.

According to 21 CFR 210.3(b)(8), an inactive ingredient is any component of a drug product other than the active ingredient. Only inactive ingredients in the final dosage forms of drug products are in this database.

India Medicine Database

Dataset consists of 8 columns : - sub_category: This classification pertains to specific medical categories that define the domain in which the medicine finds its application. - product_name: This is the name of the product, as available in the indian market. - salt_composition: This is the chemical composition of the drug. - product_price:This represents the previous price of the product. Please consider this as a reference, as it tends to be highly volatile in relation to the health market. - product_manufactured:The pharmaceutical company responsible for producing the medicine/drug. - medicine_desc: Comprehensive overview and detailed description of the specific product. - side_effects:Potential adverse effects associated with the drug/medicine. - drug_interactions:Interactions and effects when combining this specific medicine with other drugs.

There are a few missing values in the dataset, but most information is available for the row, so I have left as is.

FDA-Approved Drugs & Therapeutics

Exploring Human Drug & Biological Therapies

By Health [source]

About this dataset

This dataset contains a wealth of information about FDA-approved human drugs and biological therapeutic products. Whether you are studying the effects of drugs, exploring new treatment methods, or researching potential side effects, this database holds detailed insights into the approved medicines available to individuals today. From brand names to generic prescriptions to over-the-counter products, you can access a variety of important details such as reviews, labels, approval letters and patient information. Gain a comprehensive understanding of the drug products approved since 1939 to develop safer and more effective treatments for patients going forward

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset contains information about nearly all of the FDA-approved brand name and generic prescription drugs, as well as biological therapeutic products. It is important to note that most information is available for drug products approved since 1998, meaning that drugs approved before then may have less comprehensive data associated with them.

To get started using this dataset, you should begin by familiarizing yourself with the available columns in the dataset: - Drug Name--The name of the drug (brand name or generic). - Active Ingredient(s)--A list of active ingredients present in each drug product.
- Dosage form--The physical form and route a patient takes a specific drug product (e.g., tablet taken orally).
- Approval Description--A summary of key features and benefits related to the approval process for each product.

• Route(s) -- The manner or way by which a medication has been formulated to be absorbed or introduced into an organism's system (e.g., oral ingestion, injection).

Next, you will want to understand what type of queries can be run on this data set so that you can effectively search for specific items to analyze within your project goals:

•You can search through column headers/specific terms in order to find information related to your query such as active ingredients, dosage forms or routes used by different products;
•You can use simple comparison operators such as “=”, “<” and “>” to find ranges between certain values; •You can utilize Boolean operators such as “AND” & “OR” within SQL statements in order to combine two conditions together; •You can implement searching feature on multiple columns simultaneously using a combination of LIKE commands coupled with wildcard characters (); •Lastly you can build subqueries upon which more complicated queries are applied depending on your research objectives (these advanced scripts often incorporate functions like SUM(), AVG() etc.)

Research Ideas

• Developing a tool to help patients identify potential interactions between different drugs they are taking by cross-referencing this dataset with the patient's records.
• Developing an AI/machine learning model which evaluates all approved drugs and their effects on disease, helping physicians determine the best treatment options for their patients.
• Building an online marketplace, sponsored by health care organizations or private companies, where customers can compare prices and availability of FDA approved drugs before buying them online or in stores

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

License: Open Database License (ODbL) v1.0 - You are free to: - Share - copy and redistribute the material in any medium or format. - Adapt - remix, transform, and build upon the material for any purpose, even commercially. - You must: - Give appropriate credit - Provide a link to the license, and indicate if changes were made. - ShareAlike - You must distribute your contributions under the same license as the original. - Keep intact - all notices that refer to this license, including copyright notices. - No Derivatives - If you remix, transform, or build upon the material, you may not distribute the modified material. - No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Columns

Acknowledgements

If you use this dataset in your ...

The EU Veterinary Medicinal Product Database is intended to be a source of information on all medicinal products for veterinary use that have been authorised in the European Union and the European Economic Area. The database is hosted by the European Medicines Agency.

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...

The Table below, updated weekly, contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database. Each file on this table represents a snapshot of data in the system and is not updated by subsequent changes. Once the covered outpatient drugs in each of these files appear in the quarterly MDRP database, the file will be removed from this table. States can utilize these files to identify newly reported covered outpatient drugs.

Active drugs that have been reported by participating drug manufacturers under the Medicaid Drug Rebate Program. All drugs are identified by National Drug Code (NDC), unit type, units per package size, product name, Food and Drug Administration (FDA) approval date, the date the drug entered the market, plus indicators to show whether the drug is an innovator or non-innovator drug; whether it is available by prescription or over-the-counter (OTC); the FDA therapeutic equivalency code; and the Drug Efficacy Study Implementation (DESI) rating and termination date. Each quarter posted represents a snapshot of data in the system at that time and is not updated by subsequent changes.

Saudi Arabia Drug Database (Metadata, PILs & SPCs) - AR/EN

🟢 Overview

This is a comprehensive database of registered pharmaceutical products in the Kingdom of Saudi Arabia, collected from the official public portal of the Saudi Food and Drug Authority (SFDA).

This dataset is uniquely bilingual (Arabic / English) and provides rich, structured metadata (JSON). This makes it a valuable resource for researchers, students, Natural Language Processing (NLP) specialists, and data scientists interested in the healthcare and pharmaceutical informatics sectors in the Middle East.

🔑 Key Features

• Rich Metadata: Each drug includes detailed structured data (see "Data Structure" below), such as official price, trade and generic names, legal classification, manufacturer, agent, and storage conditions.
• Bilingual (AR/EN): Provides the "Patient Information Leaflet" (PIL) in both Arabic and English, opening significant opportunities for bilingual NLP research.
• Specialized Leaflets (SPCs): Contains the "Summary of Product Characteristics" (SPC), the technical leaflet aimed at healthcare professionals, which provides in-depth technical data.
• Processor-Ready Format (JSON): The data is organized in a JSON format, making it easy to parse and process programmatically.
• Comprehensive: The vast majority of drug records contain the full set of metadata and all three associated leaflets.

🗂️ Data Structure

The dataset is provided as a single .zip archive which contains 563 individual JSON files.

• Each JSON file contains a list of 15 drug records.
• Each drug record is an object containing its metadata and the three leaflet texts.

Example Single Drug Record

Each drug record contains a Drug Data object (the metadata) and three keys for the leaflets:

json{
 "Drug Data": {
  "Registration Number": "0202256789",
  "Register Year": "2025",
  "Trade Name": "Brevie",
  "Generic Name": "BRIVARACETAM",
  "Strength": "50",
  "Strength Unit": "mg",
  "Administration Route": "Oral use",
  "Pharmaceutical Form": "Film-coated tablet",
  "Package Size": "60",
  "Packages Types": "Blister",
  "Legal Classification": "Prescription",
  "Product Control": "Uncontrolled",
  "Drug Type": "Generic",
  "ShelfLife in Months": "36",
  "Storage Conditions": "do not store above 30°c",
  "Public price (SAR)": "266.05",
  "Manufacture": "MSN LABORATORIES PRIVATE LIMITED",
  "الوكيل": "SUDAIR PHARMA COMPANY",
  "Marketing Company": "SUDAIR PHARMA COMPANY"
 },
 "Patient Information Leaflet (PIL) in English": "[...English leaflet text...]",
 "Patient Information Leaflet (PIL) in Arabic": "[...Arabic leaflet text...]",
 "Summary of Product Characteristics (SPC)": "[...Healthcare professional leaflet text...]"
}
````
## 🔗 Data Collection Code

The full code used to collect and structure this dataset is publicly available on GitHub:

👉 **[Data Collection Repository](https://github.com/MQushaym/web-scraping-data-collection)**

This repository contains the web scraping and data processing scripts used to compile and clean the dataset.


-----

## 🎯 Potential Use Cases

 * **AI Agents & RAG (Retrieval-Augmented Generation):**

   * **(Highly Recommended)** Building a specialized AI Agent (like a GPT or LLM assistant) that answers complex questions about Saudi-registered drugs.
   * This dataset acts as a perfect "Knowledge Base" for RAG. The agent can retrieve specific leaflets (PILs/SPCs) or structured metadata (like price, storage, manufacturer) to provide accurate, verifiable, and context-aware answers.
   * Developing advanced Q\&A systems for both patients ("Can I take this drug with X?") and professionals ("What are the contraindications for this drug?").

 * **Natural Language Processing (NLP):**

   * Building specialized medical terminology translation models (Ar/En).
   * Named Entity Recognition (NER) to identify side effects, active ingredients, and dosages from the leaflet texts.
   * Text summarization of the long SPC and PIL documents.

 * **Data Analysis & Health Informatics:**

   * Analyzing drug pricing in relation to manufacturers or drug type (Generic/Innovator).
   * Constructing knowledge graphs (KGs) that link drugs, ingredients, manufacturers, and legal classifications.
   * Studying storage conditions in relation to pharmaceutical forms.

-----

## 📄 License & Citation

This dataset is made available under the **CC BY-NC 4.0 (Attribution-NonCommercial 4.0)** license.

This means you are free to use it for **academic and research purposes** as long as you provide **attribution (citation)** and do not use it for commercial purposes.

When using this dataset, please cite as follows:

> **Data collected and structured by:** Meshal AL-Qushaym
> **Dataset:** KS...

The Canadian Clinical Drug Dataset is a drug terminology and coding system designed to allow the interchange of standardized drug and medical device information between diverse digital health systems. Some use cases include electronic prescribing, electronic medical records, medication reconciliation and analytics. It also provides for the classification and identification of defined groups of medications (called special groupings), such as narcotic and controlled drugs. It has the capacity to be used by knowledge-based vendors, clinicians, researchers, statistical users, government agencies, healthcare organisations and consumers. The data source for the CCDD is the Drug Product Database (DPD) which contains information on drugs approved by Health Canada. However, the data is modeled differently following the CCDD Editorial Guidelines which take into consideration international terminology standards. For example, DPD uses the dosage form, “tablet (delayed-release)”, whereas CCDD uses the equivalent term “gastro-resistant tablet.” The Canadian Clinical Drug Data Set does not replace the Health Canada Drug Product Database (DPD) but is published in addition to it. The scope of health products included in CCDD is limited to those classified as human in DPD (veterinary, radiopharmaceutical and disinfectant products are out of scope). Some exclusions apply within the human class but are subject to periodic review: For a full list of exclusions, please see the Scope section in the CCDD Editorial Guidelines. In addition, a limited number of medical devices that are commonly prescribed and dispensed at a community pharmacy are included. This data set was developed in collaboration with Canada Health Infoway and is also available on their Terminology Server at https://infocentral.infoway-inforoute.ca/en/tools/standards-tools/terminology-server (Free login required)

Before a drug is authorized for sale in Canada, it must be issued a DIN in accordance with the Food and Drug Regulations. Also in accordance with the Food and Drug Regulations, a manufacturer of a drug must annually, before October 1, notify Health Canada that the drug is still on the market and that all the information previously provided pertaining to the drug is correct. The Health Products and Food Branch (HPFB) commits to service delivery standard of 120 calendar days, from the receipt of annual notification, to update the Drug Product Database (DPD).